TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of cases with persistent nerve injury classified as sensory loss, paraesthesia or loss of motor neuron function
Endpoint domain: Adverse events/effects
Primary endpoint: Number of reinfections
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of adaptive immune system maturation utilizing flow cytometric analysis of lymphocytes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of respiratory tract viral infections (asymptomatic and symptomatic) as assessed by the COAST Respiratory Symptom Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Viral load of respiratory pathogens in the nasopharynx of infants with symptomatic RTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Cognitive Improvement Z-score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in PTSD Symptomology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Normalized Serum Leptin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate variability- time domain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability- frequency domain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcomes related to renal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Immune Response to the Additional Dose of Engerix™-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Begrivac
Endpoint domain: Adverse events/effects
Primary endpoint: Ticagrelor's Cmax over 1 hour post administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ticagrelor plasma concentration versus time curve (AUC0-1) over 1 hour post administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic recurrence of hallux valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proband's genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proband's phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of SCP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to SCP schedule of follow-up examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thiol/disulfide hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of circulating tumor DNA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cardio-hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NIRS correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted (SCR) Subjects in Terms of HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Factor (SCF) for HI Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hematologic improvement (HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Complete Response (cCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (PathCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley III scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Excess mortality rate ratio
Endpoint domain: Mortality/survival
Primary endpoint: Social Emotional status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pressure pain thresholds (PPT) assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DN4 - Questionnaire (DN4)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Form-36 (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global improvement on PANSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total [14C]-RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of thick smear positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative difference in parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetics of parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with arrhythmias requiring treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Child development assessed with the Bayley Scale of Infant and Toddler Development (BSID III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language skills assessed with the Language Evaluation Short form SBE-2-KT; SBE-3-KT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Behavior assessed with the Strengths and Difficulties Questionnaire (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Guanylate triphosphate cyclohydrolase (GTP-CH) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC[0-inf]) of Alectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of visual assessment vs quantificational analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Opioid and Other Substance Use
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Medication-Compliant Months Across All Participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in the Number of Seizures With Associated Oxygen Desaturations Below 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in number of regulatory T-cells at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in number of regulatory T-cells at 22 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic activity of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pupil Dilation Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPA on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPA on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to identification of critical view of safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in function (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Pre-specified Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-specific B-Cell and T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoregulatory mechanisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative burden of HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery Rates of Reflux Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: American Shoulder and Elbow Society (ASES) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcomes Measurement Information Systems (PROMIS)-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: regional MRSI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DTI anisotropy measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain volumetric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients able to self-administer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Myeloma response outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events greater than grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Emotion recognition ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valence ratings of social tactile stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Score of the Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of FMD (Flow Mediated Dilatation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurocognitive function as measured by Trial Making Test (TMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive function as measured by WAIS-III (5 subtest IQ estimate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive function as measured by Hopkins Verbal Learning Test-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gustatory function alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional differences in intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlation between biomarkers and clinical indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index (kg/m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist and hip circumferences (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Oxytocin to Obtain Satisfactory Uterine Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Major complications or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Maximum Volumetric Breast Density Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of new users of SGLT-2 inhibitors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Dose Limiting Toxicities for M6620 (Berzosertib) with Radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicities for M6620 (Berzosertib) with Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Best Tolerated M6620 (Berzosertib) Treatment Schedule
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients engrafted by day +30 post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain via the Pain Catastrophizing Scale (PCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain via the Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient anxiety via State Trait Anxiety Inventory - Trait (STAI-T)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Marijuana Craving Questionnaire-Short Form Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glomerular filtration rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: thioredoxin reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Concordant CST001 Assay Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LL-37 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to therapy as evaluated by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to therapy as evaluated by Choi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Side effects/adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Subjects Who Lost More Than 5% of Body Weight From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of MQ-AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBD Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Questionnaire for Children With Inflammatory Bowel Disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Likelihood of Being Identified as Having a Mental Health Need
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Duration of Active Phase of Labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: AUC ratio of AZA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of sclerotomy site suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of suture bleb formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total exercise duration at a constant submaximal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days hospitalized for psychosis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Characterization of colorectal tissue microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oesophagus compressibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Renal Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sodium and Lithium Clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24h Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance of Implanon
Endpoint domain: Adverse events/effects
Primary endpoint: Change on the Warwick Edinburgh Mental Well-being Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on the Communication Activities of Daily Living test (CADL-2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in The Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Patient satisfaction with the rehabilitation regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of patients requiring colectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean percent of recorded adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Measure Yourself Concerns and Wellbeing (MYCAW)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in serum aspartate aminotransferase and alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Systolic dysfunction measured by ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety assessment via Adverse Events reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in Attention Network Task Conflict Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Team-based non-technical skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: NICU Admission Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) (area under the plasma concentration vs time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Treadmill Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Subjective Quality of Life Evaluation compared to Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Metabolism of alitretinoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cytokine quantification (IL1-β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine quantification (IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine quantification (IL-13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine quantification (IL-18)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine quantification (CXCL10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first ocular exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence levels in normal and tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a Confirmed Diagnosis of PCD or PID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FEV1 Percent Predicted Values in PCD and PID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Incidence of Non-relapse Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Malignant potential of pancreatic cyst measured by Interleukin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Malignant potential of pancreatic cyst measured by TNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rates of Screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in quantitative levels of s-CD95-L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose tolerance via oral glucose tolerance test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose tolerance via intravenous glucose tolerance test (IVGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Basal endogenous glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes